Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2

Andreas Mores, Magdalini Matziari, Fabrice Beau, Philippe Cuniasse, Athanasios Yiotakis, Vincent Dive*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Abstract

Angiotensin-Converting enzyme 2 (ACE2), a recently identified human homologue of angiotensin-converting enzyme, is a zinc metallocarboxypeptidase which may play a unique role in cardiovascular and renal function. Here we report the discovery of potent and selective inhibitors of ACE2, which have been identified by evaluating a series of phosphinic di- and tripeptides of the general formula: Z-Xaa(PO2-CH2)YaaOH and Ac-Zaa-Xaa(PO2-CH2)YaaOH. The most potent inhibitor in this series is a tripeptide that displays a K value of 0.4 nM toward ACE2 and is 3 orders of magnitude less potent toward carboxypeptidase A. Phosphinic tripeptides exhibit high potency exclusively when the Xaa position is occupied by a pseudoproline. A model of interaction between one inhibitor of this series and ACE2 suggests that the critical role played by a proline in inhibitors, but also for substrates hydrolysis, may rely on the presence of Tyr510 in the ACE2 active site.

Original languageEnglish
Pages (from-to)2216-2226
Number of pages11
JournalJournal of Medicinal Chemistry
Volume51
Issue number7
DOIs
Publication statusPublished - 10 Apr 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2'. Together they form a unique fingerprint.

Cite this